vs
Side-by-side financial comparison of F&G Annuities & Life, Inc. (FG) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
F&G Annuities & Life, Inc. is the larger business by last-quarter revenue ($1.8B vs $1.5B, roughly 1.2× BeOne Medicines Ltd.). F&G Annuities & Life, Inc. runs the higher net margin — 7.3% vs 4.4%, a 2.8% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 13.2%). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 6.1%).
F&G Annuities & Life, Inc. is a public company headquartered in Des Moines, Iowa. It primarily provides annuities, life insurance, and pension buyout services. The company was founded in 1959.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
FG vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.5B |
| Net Profit | $128.0M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | — | 12.4% |
| Net Margin | 7.3% | 4.4% |
| Revenue YoY | 13.2% | 32.8% |
| Net Profit YoY | -60.9% | 143.8% |
| EPS (diluted) | $0.97 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.8B | $1.5B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $908.0M | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.4B | $1.0B | ||
| Q2 24 | $1.2B | $929.2M | ||
| Q1 24 | $1.6B | $751.7M |
| Q4 25 | $128.0M | $66.5M | ||
| Q3 25 | $118.0M | $124.8M | ||
| Q2 25 | $40.0M | $94.3M | ||
| Q1 25 | $-21.0M | $1.3M | ||
| Q4 24 | $327.0M | $-151.9M | ||
| Q3 24 | $-6.0M | $-121.3M | ||
| Q2 24 | $203.0M | $-120.4M | ||
| Q1 24 | $115.0M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | -7.0% | ||
| Q3 24 | — | -12.0% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -34.8% |
| Q4 25 | 7.3% | 4.4% | ||
| Q3 25 | 7.0% | 8.8% | ||
| Q2 25 | 2.9% | 7.2% | ||
| Q1 25 | -2.3% | 0.1% | ||
| Q4 24 | 21.0% | -13.5% | ||
| Q3 24 | -0.4% | -12.1% | ||
| Q2 24 | 17.3% | -13.0% | ||
| Q1 24 | 7.3% | -33.4% |
| Q4 25 | $0.97 | $0.05 | ||
| Q3 25 | $0.85 | $0.08 | ||
| Q2 25 | $0.26 | $0.06 | ||
| Q1 25 | $-0.20 | $0.00 | ||
| Q4 24 | $2.53 | $-0.10 | ||
| Q3 24 | $-0.08 | $-0.09 | ||
| Q2 24 | $1.55 | $-0.09 | ||
| Q1 24 | $0.88 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5B | $4.5B |
| Total DebtLower is stronger | $2.2B | $836.4M |
| Stockholders' EquityBook value | $4.8B | $4.4B |
| Total Assets | $98.4B | $8.2B |
| Debt / EquityLower = less leverage | 0.47× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $4.5B | ||
| Q3 25 | $2.2B | $4.0B | ||
| Q2 25 | $1.9B | $2.8B | ||
| Q1 25 | $3.3B | $2.5B | ||
| Q4 24 | $2.3B | $2.6B | ||
| Q3 24 | $3.5B | $2.7B | ||
| Q2 24 | $3.5B | $2.6B | ||
| Q1 24 | $2.4B | $2.8B |
| Q4 25 | $2.2B | $836.4M | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $4.8B | $4.4B | ||
| Q3 25 | $4.8B | $4.1B | ||
| Q2 25 | $4.4B | $3.8B | ||
| Q1 25 | $4.4B | $3.5B | ||
| Q4 24 | $4.0B | $3.3B | ||
| Q3 24 | $4.3B | $3.4B | ||
| Q2 24 | $3.7B | $3.4B | ||
| Q1 24 | $3.5B | $3.4B |
| Q4 25 | $98.4B | $8.2B | ||
| Q3 25 | $96.1B | $7.6B | ||
| Q2 25 | $91.8B | $6.3B | ||
| Q1 25 | $88.0B | $5.8B | ||
| Q4 24 | $85.0B | $5.9B | ||
| Q3 24 | $84.1B | $5.8B | ||
| Q2 24 | $78.5B | $5.7B | ||
| Q1 24 | $74.4B | $5.7B |
| Q4 25 | 0.47× | 0.19× | ||
| Q3 25 | 0.46× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2B | $417.3M |
| Free Cash FlowOCF − Capex | — | $379.8M |
| FCF MarginFCF / Revenue | — | 25.4% |
| Capex IntensityCapex / Revenue | — | 2.5% |
| Cash ConversionOCF / Net Profit | 9.13× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $417.3M | ||
| Q3 25 | $937.0M | $402.6M | ||
| Q2 25 | $1.6B | $263.6M | ||
| Q1 25 | $956.0M | $44.1M | ||
| Q4 24 | $1.3B | $75.2M | ||
| Q3 24 | $2.1B | $188.4M | ||
| Q2 24 | $1.1B | $-95.6M | ||
| Q1 24 | $1.5B | $-308.6M |
| Q4 25 | — | $379.8M | ||
| Q3 25 | — | $354.5M | ||
| Q2 25 | — | $219.8M | ||
| Q1 25 | — | $-12.3M | ||
| Q4 24 | — | $-17.3M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $-205.5M | ||
| Q1 24 | — | $-465.1M |
| Q4 25 | — | 25.4% | ||
| Q3 25 | — | 25.1% | ||
| Q2 25 | — | 16.7% | ||
| Q1 25 | — | -1.1% | ||
| Q4 24 | — | -1.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | -22.1% | ||
| Q1 24 | — | -61.9% |
| Q4 25 | — | 2.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 11.8% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | 9.13× | 6.28× | ||
| Q3 25 | 7.94× | 3.22× | ||
| Q2 25 | 40.50× | 2.79× | ||
| Q1 25 | — | 34.71× | ||
| Q4 24 | 4.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.20× | — | ||
| Q1 24 | 13.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
